Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma

Leukemia. 2014 Feb;28(2):407-10. doi: 10.1038/leu.2013.249. Epub 2013 Aug 27.

Authors

M Axelrod¹, Z Ou², L K Brett³, L Zhang², E R Lopez², A T Tamayo², V Gordon¹, R J Ford⁴, M E Williams³, L V Pham⁴, M J Weber¹, M L Wang²

Affiliations

¹ Department of Microbiology, Immunology and Cancer Biology, University of Virginia Health System, Charlottesville, VA, USA.
² Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA USA.
⁴ Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Agammaglobulinaemia Tyrosine Kinase
Cell Line, Tumor
Drug Screening Assays, Antitumor* / methods
Drug Synergism
Humans
Lymphoma, Mantle-Cell / drug therapy
Lymphoma, Mantle-Cell / metabolism*
Proteasome Endopeptidase Complex / metabolism*
Proteasome Inhibitors / pharmacology*
Protein Kinase Inhibitors / pharmacology*
Protein-Tyrosine Kinases / antagonists & inhibitors*
Protein-Tyrosine Kinases / metabolism

Substances

Proteasome Inhibitors
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Agammaglobulinaemia Tyrosine Kinase
Proteasome Endopeptidase Complex

Grants and funding